DALLAS, April 29, 2025 Glucagon-like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) agonists originally developed to treat people with diabetes and obesity are showing promise for improving cardiovascular outcomes, but their effects can vary across different populations[1]
Providing a diverse range of dietary supplement products across multiple dosage forms allows supplement distributors to cater to regional consumer preferences , accelerate adoption, and meet the growing global demand for weight management and gut health solutions
Do the GLP-1 patches help with weight loss
Anthony Baklouk programs personal training
Combined with a healthy diet and exercise routine, this GLP-1 supplement can become an important part of your overall wellness plan
Direct evidence of GLP-1 agonists triggering MS relapses is limited, but these medications do have immunomodulatory effects